Filbrandt Wealth Management’s Novavax NVAX Stock Holding History

Filbrandt Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15	Closed	-$1K	–	286
2020 Q2	$1K	Buy	+15	New	+$574	﹤0.01%	344

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Filbrandt Wealth Management's NVAX Position: Q3 2020 in Review

Filbrandt Wealth Management sold out of Novavax (NVAX) in Q3 2020, closing a stake of 15 shares — an estimated $1K sold.

Filbrandt Wealth Management first reported a position in NVAX in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 311 funds tracked by Wall St. Rank hold NVAX as of Q3 2020.

Filbrandt Wealth Management reported no remaining Novavax position as of Q3 2020 after selling out during the quarter.
Filbrandt Wealth Management sold 15 Novavax shares in Q3 2020, an estimated $1K.
Filbrandt Wealth Management first reported a position in Novavax in Q2 2020 and held it in 1 quarter.
Filbrandt Wealth Management's Novavax position peaked at $1K in Q2 2020.
311 funds tracked by Wall St. Rank held Novavax as of Q3 2020.

Based on Filbrandt Wealth Management's 13F filing for Q3 2020, filed 29 Oct 2020.